Sign Up
Stories
Balt's Breakthrough in Sub-Dural Hematoma Treatment
Share
ACTICOR BIOTECH Delays Key Documents
Advanced Technology Saves Patient's Life
Deep Vein Thrombosis Market Set for Grow...
BiVACOR Appoints New Chairman
BiVACOR Welcomes New CEO and FDA Approva...
Fashion Designer's Health Update
Overview
API
Balt, Inc. presents preliminary data from The Squid Trial for the treatment of chronic Sub-Dural Hematoma, demonstrating low complication rates and potential treatment success. The trial involved 310 subjects and aims to bring the technology to the US, focusing on neurovascular conditions.
Ask a question
How could this breakthrough potentially influence other research and development in the neurovascular devices sector?
How might the success of The Squid Trial impact the treatment landscape for chronic Sub-Dural Hematoma?
What challenges might Balt, Inc. face in bringing the technology to the US market?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage